Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine.
about
Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primatesVesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primatesVesicular stomatitis virus with the rabies virus glycoprotein directs retrograde transsynaptic transport among neurons in vivoHuman coronaviruses: insights into environmental resistance and its influence on the development of new antiseptic strategiesSevere acute respiratory syndrome coronavirus as an agent of emerging and reemerging infectionVaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variantsA decade after SARS: strategies for controlling emerging coronavirusesVesicular stomatitis virus vectors expressing avian influenza H5 HA induce cross-neutralizing antibodies and long-term protection.Characterization of a Bivalent Vaccine Capable of Inducing Protection Against Both Ebola and Cross-clade H5N1 Influenza in MicePotent vesicular stomatitis virus-based avian influenza vaccines provide long-term sterilizing immunity against heterologous challenge.In Vitro and In Vivo Attenuation of Vesicular Stomatitis Virus (VSV) by Phosphoprotein Deletion.Immunogenicity and protective efficacy in mice and hamsters of a β-propiolactone inactivated whole virus SARS-CoV vaccineVesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus.Neurovirulence and immunogenicity of attenuated recombinant vesicular stomatitis viruses in nonhuman primates.A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunityCoronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus.Stimulation of human dendritic cells by wild-type and M protein mutant vesicular stomatitis viruses engineered to express bacterial flagellin.Acute reactogenicity after intramuscular immunization with recombinant vesicular stomatitis virus is linked to production of IL-1βRecombinant vesicular stomatitis virus vectors expressing herpes simplex virus type 2 gD elicit robust CD4+ Th1 immune responses and are protective in mouse and guinea pig models of vaginal challenge.Complementing defective viruses that express separate paramyxovirus glycoproteins provide a new vaccine vector approach.Vesicular stomatitis virus as a vector to deliver virus-like particles of human norovirus: a new vaccine candidate against an important noncultivable virus.Emerging respiratory viruses: challenges and vaccine strategiesVesicular stomatitis virus-based H5N1 avian influenza vaccines induce potent cross-clade neutralizing antibodies in rhesus macaques.Nonsegmented negative-strand viruses as vaccine vectors.Synergistic attenuation of vesicular stomatitis virus by combination of specific G gene truncations and N gene translocations.Utility of the aged BALB/c mouse model to demonstrate prevention and control strategies for severe acute respiratory syndrome coronavirus (SARS-CoV)Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primatesNewcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens.Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus.Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in miceChimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoVA chimeric vesiculo/alphavirus is an effective alphavirus vaccineVaccines to prevent severe acute respiratory syndrome coronavirus-induced disease.Single-dose live-attenuated Nipah virus vaccines confer complete protection by eliciting antibodies directed against surface glycoproteins.Immune response in the absence of neurovirulence in mice infected with m protein mutant vesicular stomatitis virus.Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection againstSingle-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection.Prime-boost vaccination with recombinant mumps virus and recombinant vesicular stomatitis virus vectors elicits an enhanced human immunodeficiency virus type 1 Gag-specific cellular immune response in rhesus macaques.Single-dose replication-defective VSV-based Nipah virus vaccines provide protection from lethal challenge in Syrian hamsters.Single injection recombinant vesicular stomatitis virus vaccines protect ferrets against lethal Nipah virus disease.
P2860
Q21090120-C3B66D41-7AF0-4CC8-9E00-DF44E46B9468Q21131585-EBC821F8-414B-4523-BDEE-FC1B7C3EBEB5Q24625780-17DDC187-4A74-4D9E-A13A-696D28F59276Q27011643-60752E4C-8589-4F98-B088-FC27150A639FQ28383088-0B5EFDF2-CEE3-4FCE-8427-535F0C255EFDQ28764574-26E3C51B-FDB7-4094-8E1D-15F7D6DACB4EQ28817689-157A3A07-5076-4DE1-ABFD-8DFF0F74F6B0Q30361939-77FD8933-127E-46E6-87FE-5F0E23C1E8A2Q30375073-036A75BA-46AF-4EB0-8744-1CDD25CC72F2Q30385999-A14FF4FB-2043-4728-BC90-A7945B464A7CQ30389455-12B45508-BCF8-455F-8861-D3F9125D0ED7Q30430552-B1DF9CAF-37CD-402A-AFB5-FB814A828206Q33713083-FBFFD009-5B63-4D08-9204-F147F19B2499Q33743852-75B7BAE2-0056-423B-AAC9-9EE402DE9C43Q33904997-3B456E16-B4A9-4701-9190-053E4023A3D6Q34193942-C4157367-F723-415C-A17B-51D55AB948D7Q34296055-5071D95B-BEB3-4CC7-91D9-3172337599E4Q34441577-56B911F7-12A0-4E8A-98CC-5A62EBAEA65FQ34647625-FFB4B3A3-1794-435B-84B7-0404DA658136Q34741896-8D92DF8D-5CA9-4290-B7AA-1634B061B30CQ34742846-E6AA2A4D-9201-49DC-8DCE-30793F3BFEFFQ35070868-CFE0810E-E4B6-4A6B-BDEE-ACB2FEF87279Q35076920-B9831744-4454-43C5-B6B9-67A6A6ADF4B9Q35139219-A07A32B2-8934-4A67-AAE3-75A32A1DA4C6Q35635393-0297290F-E2C7-47F1-9990-593601E8AC6FQ35740733-2C3C972C-EDE8-4A8C-A35C-7226772F1E1EQ35781967-3217326E-D1ED-427E-9BFD-AD4C94BEF9C5Q35834369-F5F4F5C0-54C8-4B5A-809F-0FC01720F58BQ36043290-7234CEC6-4231-47E2-9FEC-AE54A499B44EQ36423935-C5723A19-6D2A-495E-BAA9-478FF4034448Q36496355-16673359-BAD1-413B-94FD-369A3D520552Q36506753-424A43D1-4D74-489F-833B-F03C7CA3BE2AQ36784740-77E6B6BD-BA41-4637-8578-75E122D947A7Q36791009-4E761117-C2C5-441A-A667-162C95FDE8E3Q36898706-F2116004-7B52-4B71-91DC-9EA208C987D9Q37015424-63A20952-C619-4F6E-96B9-8E46E4055CEEQ37066697-CD04F35A-FCFE-4C90-8FD1-C05550314142Q37355979-139AA75E-337B-4869-AE88-9F6A100478B8Q37418736-EB286762-3905-4E00-87FC-6FFE6F3D6239Q37427047-6CB313DC-9902-4E63-B507-9A467906BA3A
P2860
Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Long-term protection from SARS ...... attenuated VSV-based vaccine.
@en
type
label
Long-term protection from SARS ...... attenuated VSV-based vaccine.
@en
prefLabel
Long-term protection from SARS ...... attenuated VSV-based vaccine.
@en
P2093
P921
P1433
P1476
Long-term protection from SARS ...... attenuated VSV-based vaccine.
@en
P2093
Elaine Lamirande
John K Rose
Leatrice Vogel
Sagar U Kapadia
P304
P356
10.1016/J.VIROL.2005.06.016
P407
P577
2005-09-01T00:00:00Z